Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Allergenic Products Advisory Committee

Executive Summary

Will meet July 20 to consider presentations on the Center for Biologics Evaluation and Research Division of Allergenic Products and Parasitology's labs of Immunoregulation, Immunobiochemistry, Parasitology and Biochemistry, and Biophysics. The committee also will hear presentations on conversions of radioallergosorbent test (RAST) inhibition assay to the enzyme-linked immunosorbent assay (ELISA); the points to consider document for production and testing of allergenic products; marker proteins, monoclonal antibodies and automation; and conversion of standardized grass pollen extracts to bioequivalent allergy units. The meeting will begin at 8:30 a.m. at the Holiday Inn, Bethesda, Md. Closed committee deliberations will begin at 12:30 p.m.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022809

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel